Cresset Asset Management LLC Acquires 210,267 Shares of Tilray Brands, Inc. $TLRY

Cresset Asset Management LLC increased its holdings in shares of Tilray Brands, Inc. (NASDAQ:TLRY) by 72.1% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 501,989 shares of the company’s stock after purchasing an additional 210,267 shares during the quarter. Cresset Asset Management LLC’s holdings in Tilray Brands were worth $868,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Optiver Holding B.V. lifted its holdings in Tilray Brands by 239.4% in the 3rd quarter. Optiver Holding B.V. now owns 224,049 shares of the company’s stock worth $388,000 after purchasing an additional 158,041 shares in the last quarter. Clearstead Advisors LLC grew its holdings in Tilray Brands by 437.3% during the 3rd quarter. Clearstead Advisors LLC now owns 21,625 shares of the company’s stock valued at $37,000 after buying an additional 17,600 shares in the last quarter. Cibc World Market Inc. grew its holdings in Tilray Brands by 93.8% during the 3rd quarter. Cibc World Market Inc. now owns 55,123 shares of the company’s stock valued at $95,000 after buying an additional 26,677 shares in the last quarter. Baader Bank Aktiengesellschaft raised its position in shares of Tilray Brands by 29.5% during the third quarter. Baader Bank Aktiengesellschaft now owns 439,997 shares of the company’s stock valued at $761,000 after buying an additional 100,291 shares during the last quarter. Finally, Oppenheimer & Co. Inc. purchased a new position in shares of Tilray Brands in the third quarter worth $25,000. Institutional investors own 9.35% of the company’s stock.

Tilray Brands Price Performance

TLRY stock opened at $7.20 on Wednesday. Tilray Brands, Inc. has a 52 week low of $3.51 and a 52 week high of $23.20. The firm has a market capitalization of $838.87 million, a P/E ratio of -0.33 and a beta of 1.96. The company has a fifty day simple moving average of $8.22 and a two-hundred day simple moving average of $10.90. The company has a quick ratio of 1.72, a current ratio of 2.81 and a debt-to-equity ratio of 0.19.

Tilray Brands (NASDAQ:TLRY) last posted its earnings results on Thursday, January 8th. The company reported ($0.02) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.12. The firm had revenue of $217.51 million for the quarter, compared to the consensus estimate of $211.15 million. Tilray Brands had a negative net margin of 251.69% and a negative return on equity of 6.35%. During the same period in the previous year, the firm posted ($0.03) EPS. Analysts anticipate that Tilray Brands, Inc. will post -0.2 earnings per share for the current fiscal year.

Key Stories Impacting Tilray Brands

Here are the key news stories impacting Tilray Brands this week:

• Positive Sentiment: Tilray completed the acquisition of BrewDog’s Australian brewing and bar assets, giving it a profitable operational base (brewery + flagship bars) to scale across Australia and the Asia‑Pacific — a direct step to grow its beverage and CPG business beyond North America. Tilray Brands Acquires BrewDog Australia
• Positive Sentiment: Management is projecting much larger top-line growth (Tilray expects roughly $1.2B in revenue next year) driven by acquisitions and expanded beverage distribution; management also cites BrewDog-related revenue targets (e.g., ~$200M annual net revenue from UK operations by FY2027), supporting the company’s multi‑brand growth thesis. Tilray Brands Expects to Generate $1.2 Billion
• Neutral Sentiment: Broader industry coverage highlights continued global legalization and investor interest in Canadian cannabis names, which can support long‑term demand assumptions for diversified cannabis/CPG players like Tilray but does not change near‑term company fundamentals. Canadian Cannabis Stocks to Watch in March 2026
• Negative Sentiment: Analyst commentary and investor debate flag near‑term execution risk: integration costs, margin pressure and the need to prove Project 420 synergies. Recent writeups call Tilray a “hold” until synergies materialize. The company still reports negative net margins and ROE, and some analysts model negative EPS for the current fiscal year — all factors that can prompt profit‑taking and keep the stock under pressure. Tilray’s Going To Be Great, But For Now It’s A Hold

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on the stock. Zacks Research upgraded shares of Tilray Brands from a “strong sell” rating to a “hold” rating in a research report on Wednesday, February 11th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Tilray Brands in a report on Wednesday, January 21st. ATB Cormark Capital Markets upgraded shares of Tilray Brands from a “strong sell” rating to a “hold” rating in a research note on Wednesday, December 10th. Roth Mkm dropped their price objective on shares of Tilray Brands from $20.00 to $10.00 and set a “neutral” rating for the company in a report on Tuesday, January 20th. Finally, Wall Street Zen lowered Tilray Brands from a “hold” rating to a “sell” rating in a research report on Saturday. One investment analyst has rated the stock with a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $13.33.

About Tilray Brands

Tilray Brands, Inc is a global cannabis-lifestyle and consumer packaged goods company engaged in the cultivation, production, distribution and sale of cannabis and cannabinoid-based products. The company develops and markets a diverse portfolio of branded products spanning medical cannabis, adult-use recreational products and wellness offerings. Through state-of-the-art cultivation facilities, research and development efforts, and quality control systems, Tilray Brands aims to deliver consistent, scalable products for a range of patient and consumer needs.

Tilray’s product lineup includes cannabis flower, pre-rolls, oils and tinctures, vapes, edibles and topicals, as well as hemp-derived cannabidiol (CBD) products.